Ependymoma - Pipeline Review, Q2 2011

Description: Ependymoma - Pipeline Review, Q2 2011

Summary

Global Markets Direct's, 'Ependymoma - Pipeline Review, Q2 2011', provides an overview of the Ependymoma therapeutic pipeline. This report provides information on the therapeutic development for Ependymoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ependymoma. 'Ependymoma - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ependymoma.
- A review of the Ependymoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ependymoma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ependymoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ependymoma pipeline depth and focus of Ependymoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ependymoma Overview
Therapeutics Development
An Overview of Pipeline Products for Ependymoma
Ependymoma Therapeutics under Development by Companies
Ependymoma Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Ependymoma Therapeutics - Products under Development by Companies
Ependymoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Ependymoma Therapeutics Development
Eli Lilly and Company
OSI Pharmaceuticals, Inc.
Ependymoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antineoplason Therapy + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Lapatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Etoposide + Vincristine sulfate + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alimta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GW572016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Camptosar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Lapatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norvir + Lopinavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Sargramostim + Cyclophosphamide + Thiotepa + Peripheral Blood Stem Cell Transplantation/Autologous Bone Marrow Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine Sulfate + Carboplatin + Cyclophosphamide + Etoposide + Filgrastim + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cells + Imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tarceva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Ependymoma, Q2 2011
Products under Development for Ependymoma – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Eli Lilly and Company, 2011
OSI Pharmaceuticals, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011

List of Figures
Number of Products under Development for Ependymoma, Q2 2011
Products under Development for Ependymoma – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Ordering:
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Ependymoma - Pipeline Review, Q2 2011
Web Address: http://www.researchandmarkets.com/reports/1841885/
Office Code: SCD22DV2

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World